Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

Abstract: Methods, computer programs and databases for determining haplotypes from a collection of polymorphisms are provided. These include methods, programs, and databases to find and measure the frequency of haplotypes in the general population; and methods, programs, and databases for predicting an individual's haplotypes from the individual's genotype for a gene.

Abstract: Novel genetic variants of the Tumor Necrosis Factor Receptor Superfamily, Member 11b (Osteoprotegerin) (TNFRSF11B) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the TNFRSF11B gene. Compositions and methods for haplotyping and/or genotyping the TNFRSF11B gene in an individual are also disclosed. Polynucleotides defined by the haplotypes disclosed herein are also described.

Abstract: Novel genetic variants of the Tumor Necrosis Factor Receptor Superfamily, Member 1A (TNFRSF1A) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the TNFRSF1A gene. Compositions and methods for haplotyping and/or genotyping the TNFRSF1A gene in an individual are also disclosed. Polynucleotides defined by the haplotypes disclosed herein are also described.

Abstract: Genotypes and haplotypes for thirteen polymorphic sites in the &bgr;2-adrenergic receptor (&bgr;2AR) gene are disclosed. Compositions and methods for predicting genetic predisposition to disease associated with polymorphic sites in the (&bgr;2AR) gene, as well as for predicting response to &bgr;-agonists, are also disclosed.

Abstract: Genotypes and haplotypes for thirteen polymorphic sites in the &bgr;2-adrenergic receptor (&bgr;2AR) gene are disclosed. Compositions and methods for predicting genetic predisposition to disease associated with polymorphic sites in the (&bgr;2AR) gene, as well as for predicting response to &bgr;-agonists, are also disclosed.

Abstract: Genotypes and haplotypes for thirteen polymorphic sites in the &bgr;2-adrenergic receptor (&bgr;2AR) gene are disclosed. Compositions and methods for predicting genetic predisposition to disease associated with polymorphic sites in the (&bgr;2AR) gene, as well as for predicting response to &bgr;-agonists, are also disclosed.

Abstract: Genotypes and haplotypes for thirteen polymorphic sites in the &bgr;2-adrenergic receptor (&bgr;2AR) gene are disclosed. Compositions and methods for predicting genetic predisposition to disease associated with polymorphic sites in the (&bgr;2AR) gene, as well as for predicting response to &bgr;-agonists, are also disclosed.